1
|
Ityonzughul C, Sallau A, Miri E, Emukah E, Kahansim B, Adelamo S, Chiedo G, Ifeanyichukwu S, Coalson JE, Rakers L, Griswold E, Makata C, Oyediran F, Osuji S, Offor S, Obikwelu E, Otiji I, Richards FO, Noland GS. The Interruption of Transmission of Onchocerciasis in Abia, Anambra, Enugu, and Imo States, Nigeria: The Largest Global Onchocerciasis Stop-Treatment Decision to Date. Pathogens 2024; 13:671. [PMID: 39204271 PMCID: PMC11356909 DOI: 10.3390/pathogens13080671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2024] [Revised: 07/30/2024] [Accepted: 08/01/2024] [Indexed: 09/03/2024] Open
Abstract
Onchocerciasis causes severe morbidity in sub-Saharan Africa. Abia, Anambra, Enugu, and Imo states of Nigeria were historically classified meso- or hyperendemic and eligible for ivermectin mass drug administration (MDA). After ≥25 years of annual and biannual MDA, serological and entomological assessments were conducted to determine if Onchocerca volvulus transmission was interrupted. Dried blood spots collected in October 2020 from ≥3167 children 5-9 years old in each state were screened for O. volvulus-specific Ov16 antibody by enzyme-linked immunosorbent assay. Additionally, 52,187 Simulium damnosum heads (≥8845 per state) collected over 12 months between 2021 and 2022 were tested by pooled polymerase chain reaction (PCR) for O-150 DNA. Among seven seropositive children, four were found for follow-up skin snip PCR to confirm active infection. Three were negative and the fourth was excluded as he was visiting from an endemic state. The final seroprevalence estimates of each state had 95% upper confidence limits (UCL) < 0.1%. All fly pools were negative by O-150 PCR, giving a 95% UCL infective fly prevalence < 0.05% in each state. Each state therefore met the World Health Organization epidemiological and entomological criteria for stopping MDA effective January 2023. With 18.9 million residents eligible for MDA, this marked the largest global onchocerciasis stop-treatment decision to date.
Collapse
Affiliation(s)
- Cephas Ityonzughul
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Adamu Sallau
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Emmanuel Miri
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Emmanuel Emukah
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Barminas Kahansim
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Solomon Adelamo
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - George Chiedo
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Samuel Ifeanyichukwu
- The Carter Center, Jos 930104, Nigeria; (A.S.); (E.M.); (E.E.); (B.K.); (S.A.); (G.C.); (S.I.)
| | - Jenna E. Coalson
- The Carter Center, Atlanta, GA 30307, USA; (J.E.C.); (L.R.); (E.G.); (F.O.R.J.); (G.S.N.)
| | - Lindsay Rakers
- The Carter Center, Atlanta, GA 30307, USA; (J.E.C.); (L.R.); (E.G.); (F.O.R.J.); (G.S.N.)
| | - Emily Griswold
- The Carter Center, Atlanta, GA 30307, USA; (J.E.C.); (L.R.); (E.G.); (F.O.R.J.); (G.S.N.)
| | - Chukwuemeka Makata
- Federal Ministry of Health and Social Welfare, Abuja 900242, Nigeria; (C.M.); (F.O.)
| | - Fatai Oyediran
- Federal Ministry of Health and Social Welfare, Abuja 900242, Nigeria; (C.M.); (F.O.)
| | - Stella Osuji
- Imo State Ministry of Health, Owerri 460281, Nigeria;
| | - Solomon Offor
- Abia State Ministry of Health, Umuahia 440236, Nigeria;
| | | | - Ifeoma Otiji
- Enugu State Ministry of Health, Enugu 400105, Nigeria;
| | - Frank O. Richards
- The Carter Center, Atlanta, GA 30307, USA; (J.E.C.); (L.R.); (E.G.); (F.O.R.J.); (G.S.N.)
| | - Gregory S. Noland
- The Carter Center, Atlanta, GA 30307, USA; (J.E.C.); (L.R.); (E.G.); (F.O.R.J.); (G.S.N.)
| |
Collapse
|
2
|
Mansour A, Rodriguez L, Mansour H, Yehia M, Battaglia Parodi M. Presumed Onchocerciasis Chorioretinitis Spilling over into North America, Europe and Middle East. Diagnostics (Basel) 2023; 13:3626. [PMID: 38132210 PMCID: PMC10743067 DOI: 10.3390/diagnostics13243626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 11/26/2023] [Accepted: 11/30/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Newer generation ophthalmologists practicing in the developed world are not very familiar with some tropical ocular diseases due to the absence of reports in the ophthalmic literature over the past thirty years. Because of world globalization or due to influx of immigrants from sub-Saharan Africa, exotic retinal diseases are being encountered more often in ophthalmology clinics. METHODS A multicenter case series of chorioretinitis or optic neuritis with obscure etiology that used serial multimodal imaging. RESULTS Four cases qualified with the diagnosis of presumed ocular onchocerciasis based on their residence near fast rivers in endemic areas, multimodal imaging, long term follow-up showing progressive disease and negative workup for other diseases. Characteristic findings include peripapillary choroiditis with optic neuritis or atrophy, subretinal tracts of the microfilaria, progressive RPE atrophy around heavily pigmented multifocal chorioretinal lesions of varying shapes, subretinal white or crystalline dots, and response to ivermectin. Typical skin findings are often absent in such patients with chorioretinitis rendering the diagnosis more challenging. CONCLUSIONS Familiarity with the myriad ocular findings of onchocerciasis, and a high-degree of suspicion in subjects residing in endemic areas can help in the correct diagnosis and implementation of appropriate therapy. Onchocercal chorioretinitis is a slow, insidious, progressive, and prolonged polymorphous disease.
Collapse
Affiliation(s)
- Ahmad Mansour
- Retina Service, Department of Ophthalmology, American University of Beirut, Beirut 1107, Lebanon
| | - Linnet Rodriguez
- Retina Service, Wills Eye Hospital, Thomas Jefferson Medical Center, Philadelphia, PA 19107, USA; (L.R.); (H.M.)
| | - Hana Mansour
- Retina Service, Wills Eye Hospital, Thomas Jefferson Medical Center, Philadelphia, PA 19107, USA; (L.R.); (H.M.)
| | - Madeleine Yehia
- Retina Service, University of Illinois Chicago, Chicago, IL 60612, USA;
| | - Maurizio Battaglia Parodi
- Retina Service, Department of Ophthalmology, Ospedale San Raffaele, University Vita-Salute, 20132 Milan, Italy;
| |
Collapse
|